• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.目前评估体内止血的方法综述及一种潜在替代方法的介绍。
Thromb Res. 2012 May;129 Suppl 2(0 2):S57-61. doi: 10.1016/j.thromres.2012.02.035. Epub 2012 Mar 8.
2
ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.ARFI 超声监测犬血管性血友病和血友病出血及止血的活体研究。
Ultrasound Med Biol. 2011 Dec;37(12):2126-32. doi: 10.1016/j.ultrasmedbio.2011.09.006. Epub 2011 Oct 26.
3
Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond.遗传性凝血异常：血友病、血管性血友病及其他。
Pediatr Clin North Am. 2013 Dec;60(6):1419-41. doi: 10.1016/j.pcl.2013.09.002.
4
An overview: hemophilia and hemostasis.
Prog Clin Biol Res. 1981;72:259-75.
5
Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders.在原发性止血障碍的犬模型中，颊黏膜出血时间会延长。
Thromb Haemost. 1993 Nov 15;70(5):777-80.
6
Haemostasis screening.
Br J Hosp Med (Lond). 2009 Aug;70(8):M116-8. doi: 10.12968/hmed.2009.70.Sup8.43551.
7
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.重组凝血因子VIIa对患有甲型血友病、乙型血友病和血管性血友病的犬类止血缺陷的影响。
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1382-6. doi: 10.1073/pnas.86.4.1382.
8
Sex-related differences in hemostasis and thrombosis.止血与血栓形成中的性别差异。
J Gend Specif Med. 2001;4(2):59-64.
9
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.在A型血友病、B型血友病、血管性血友病和因子VII缺乏症的犬类模型中的蛋白质替代疗法和基因转移。
ILAR J. 2009;50(2):144-67. doi: 10.1093/ilar.50.2.144.
10
Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact.止血障碍与月经过多：患病率及临床影响
Fertil Steril. 2005 Nov;84(5):1338-44. doi: 10.1016/j.fertnstert.2005.04.061.

引用本文的文献

1
Improving the adhesion, flexibility, and hemostatic efficacy of a sprayable polymer blend surgical sealant by incorporating silica particles.通过加入硅粒子来提高喷雾型聚合物混合外科密封剂的黏附性、柔韧性和止血效果。
Acta Biomater. 2019 May;90:205-216. doi: 10.1016/j.actbio.2019.04.015. Epub 2019 Apr 4.
2
Improving Displacement Signal-to-Noise Ratio for Low-Signal Radiation Force Elasticity Imaging Using Bayesian Techniques.使用贝叶斯技术提高低信号辐射力弹性成像的位移信噪比
Ultrasound Med Biol. 2016 Aug;42(8):1986-97. doi: 10.1016/j.ultrasmedbio.2016.03.004. Epub 2016 May 4.
3
Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs.在组织模拟模型和犬类中使用校准输注对皮下出血（ASSH）进行ARFI监测的实验验证
Ultrason Imaging. 2016 Sep;38(5):346-58. doi: 10.1177/0161734615617940. Epub 2015 Nov 27.
4
Lessons Learned from Animal Models of Inherited Bleeding Disorders.从遗传性出血性疾病动物模型中获得的经验教训。
Hematol Educ. 2014 Jun;8(1):39-46.

本文引用的文献

1
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.全血凝固时间和活化部分凝血活酶时间对因子IX的敏感性：与基因治疗的相关性以及血友病B犬中犬因子IX输血后消除时间的测定
J Thromb Haemost. 2012 Mar;10(3):474-6. doi: 10.1111/j.1538-7836.2011.04613.x.
2
Merry christmas for patients with hemophilia B.祝乙型血友病患者圣诞快乐。
N Engl J Med. 2011 Dec 22;365(25):2424-5. doi: 10.1056/NEJMe1111138. Epub 2011 Dec 10.
3
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.腺相关病毒载体介导的乙型血友病基因转移。
N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.
4
Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.猪和犬的血管性血友病因子及血管性血友病：止血、血栓形成和动脉粥样硬化研究
Thrombosis. 2010;2010:461238. doi: 10.1155/2010/461238. Epub 2011 Feb 7.
5
ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.ARFI 超声监测犬血管性血友病和血友病出血及止血的活体研究。
Ultrasound Med Biol. 2011 Dec;37(12):2126-32. doi: 10.1016/j.ultrasmedbio.2011.09.006. Epub 2011 Oct 26.
6
ARFI ultrasound for in vivo hemostasis assessment postcardiac catheterization, part II: pilot clinical results.用于心脏导管插入术后体内止血评估的ARFI超声，第二部分：初步临床结果
Ultrason Imaging. 2009 Jul;31(3):159-71. doi: 10.1177/016173460903100302.
7
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.在A型血友病、B型血友病、血管性血友病和因子VII缺乏症的犬类模型中的蛋白质替代疗法和基因转移。
ILAR J. 2009;50(2):144-67. doi: 10.1093/ilar.50.2.144.
8
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.通过持续表达犬FVIIa成功治疗犬血友病。
Blood. 2009 Apr 16;113(16):3682-9. doi: 10.1182/blood-2008-07-168377. Epub 2008 Dec 23.
9
What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008.重组凝血因子VIIa（rFVIIa）用于华法林急性逆转的超说明书用药依据是什么？2008年美国血液学会循证综述。
Hematology Am Soc Hematol Educ Program. 2008:36-8. doi: 10.1182/asheducation-2008.1.36.
10
Emergency reversal of antithrombotic treatment.抗栓治疗的紧急逆转
Intern Emerg Med. 2009 Apr;4(2):137-45. doi: 10.1007/s11739-008-0201-8. Epub 2008 Nov 12.

目前评估体内止血的方法综述及一种潜在替代方法的介绍。

A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

机构信息

Joint Department of Biomedical Engineering, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

出版信息

Thromb Res. 2012 May;129 Suppl 2(0 2):S57-61. doi: 10.1016/j.thromres.2012.02.035. Epub 2012 Mar 8.

DOI:10.1016/j.thromres.2012.02.035
PMID:22405050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3928126/
Abstract

A validated method for assessing hemostasis in vivo is critical for testing the hemostatic efficacy of therapeutic agents in preclinical animal models and in patients with inherited bleeding disorders, such as von Willebrand disease (VWD) and hemophilia A, or with acquired bleeding disorders such as those resulting from medications or disease processes. In this review, we discuss current methods for assessing hemostasis in vivo and the associated challenges. We also present ARFI-Monitored Hemostatic Challenge; a new, potentially alternate method for in vivo hemostasis monitoring that is in development by our group.

摘要

评估体内止血的验证方法对于在临床前动物模型和患有遗传性出血性疾病（如血管性血友病（VWD）和血友病 A）或获得性出血性疾病（如药物或疾病过程引起的出血性疾病）的患者中测试治疗剂的止血效果至关重要。在这篇综述中，我们讨论了目前用于评估体内止血的方法和相关挑战。我们还介绍了 ARFI 监测止血挑战；这是我们小组正在开发的一种新的、潜在的替代体内止血监测方法。